In a series of studies, Varenzin-CA1 was shown to have a reasonable expectation of efficacy in managing anemia in CKD cats. By day 28, 50% of cats given Varenzin-CA1 had increased their red blood ...

(RTTNews) - The U.S. Food and Drug Administration conditionally approved Elanco US Inc.'s Varenzin-CA1 (molidustat oral suspension) for treating anemia in cats with chronic kidney disease or CKD.

Elanco Launches Varenzin™-CA1 (molidustat oral suspension) – the First-of-its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease. September 07, 2023 04:15 PM Eastern Daylight Time.